Vascular Disrupting Agents Market Size is predicted to grow at an 10% CAGR during the forecast period for 2029-2034.
Vascular disrupting agents (VDAs) are a novel family of medications that target the existing tumour vasculature and cause tumour necrosis. As the world's population has aged, so has the global burden of cancer morbidity and mortality. Cancer is the primary or second leading cause of death among persons under the age of 70 in 112 of 183 countries, according to World Health Organization estimates in 2019. Vascular disrupting agents are the medications utilized in tumour vascular disrupting treatment (VDAs). VDAs can specifically target tumour vasculature via several mechanisms, inhibiting blood flow within tumours and causing widespread secondary necrosis while leaving normal tissues largely unscathed. These agents are used to treat various cancer types such as thyroid cancer, liver cancer, ovarian cancer, and colorectal cancer.
Factors driving the growth of the vascular disrupting agents market include the high prevalence rate of cancer, rising geriatric population, increasing demand for advanced cancer therapy options, growing public awareness about novel therapy treatments, increasing government expenditure for cancer therapy research and development, expiry of patents for various drugs, and the changing lifestyle standards. Furthermore, pharmaceutical companies are investing more in cancer research due to the growing list of risk factors and cancer-causing agents of existing anticancer therapies, thereby creating growth opportunities for the vascular disrupting agents market. However, the high cost of target therapies and the lack of availability of safety data may restrict the market growth in the future.
The vascular disrupting agents market is classified based on indications, therapeutic area, molecules, therapy, route of administration, product, and region. Based on the indications, the market comprises chemotherapy-induced neutropenia, glioblastoma, liver cancer, mesothelioma, non-small cell lung cancer, prostate cancer, ovarian cancer, renal pelvis, and ureter cancer. The market is segmented into hematological malignancies and solid tumors by therapeutic area. By molecules, the market is divided into tubulin binding agents, flavonoids, and ligand-directed agents. The Tubulin Binding Agents and Flavonoids segments are anticipated to expand over the forecast period as the small molecules are majorly used in the pipeline. In terms of therapy, the market is bifurcated into mono and combination. by route of administration, the market is classified into oral and intravenous. The product segment is categorized into Bavituximab, Icaritin, NGR-TNF, Padeliporfin, Plinabulin, VB-111, and others. Regionally, the market is categorized across North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa.
North America will likely hold the highest share of this market in the next few years due to the well-established healthcare infrastructures, growing elderly population, and rising patient awareness regarding the benefits of new targeted therapies.
| Report Attribute | Specifications |
| Growth rate CAGR | CAGR of 10% from 2029 to 2034 |
| Quantitative units | Representation of revenue in US$ Million and CAGR from 2029 to 2034 |
| Historic Year | 2021 to 2024 |
| Forecast Year | 2029-2034 |
| Report coverage | The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
| Segments covered | By Indication, By Therapeutic Area, By Product, By Molecule, By Therapy, By Route of Administration |
| Regional scope | North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
| Country scope | U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico ;The UK; France; Italy; Spain; South Korea; South East Asia |
| Competitive Landscape | AGC Biologics (Denmark), Avid Bioservices (US), Bionomics (Australia), Beijing Shenogen Biomedical (China), Mateon Therapeutics (US), Myrexis (US), VBL Therapeutics (Israel), Steba biotech (US), BeyondSpring Pharmaceuticals (US), Immune Pharmaceuticals (US), Nereus Pharmaceuticals (US), Madrigal Pharmaceuticals, Inc. (US), Celgene Corporation (US), Bionomics Ltd. (Australia), Lees Pharmaceutical Holdings. (Hong Kong), and others. |
| Customization scope | Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
| Pricing and available payment methods | Explore pricing alternatives that are customized to your particular study requirements. |
Global Vascular Disrupting Agents Market, by Indications, 2020-2030 (Valu US$ Mn)
Global Vascular Disrupting Agents Market, by Therapeutic Area, 2020-2030 (Valu US$ Mn)
Global Vascular Disrupting Agents Market, by Molecules, 2020-2030 (Value US$ Mn)
Global Vascular Disrupting Agents Market, by Therapy, 2020-2030 (Valu US$ Mn)
Global Vascular Disrupting Agents Market, by Route of Administration, 2020-2030 (Value US$ Mn)
Global Vascular Disrupting Agents Market, by Product, 2020-2030 (Valu US$ Mn)
Global Vascular Disrupting Agents Market, by Region, 2020-2030 (Value US$ Mn)
North America Vascular Disrupting Agents Market, by Country, 2020-2030 (Value US$ Mn)
Europe Vascular Disrupting Agents Market, by Country, 2020-2030 (Value US$ Mn)
Asia Pacific Vascular Disrupting Agents Market, by Country, 2020-2030 (Value US$ Mn)
Latin America Vascular Disrupting Agents Market, by Country, 2020-2030 (Value US$ Mn)
Middle East & Africa Vascular Disrupting Agents Market, by Country, 2020-2030 (Value US$ Mn)
Competitive Landscape
This study employed a multi-step, mixed-method research approach that integrates:
This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.
Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.
Secondary data for the market study was gathered from multiple credible sources, including:
These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.
Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.
Primary interviews for this study involved:
Interviews were conducted via:
Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.
All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.
The data validation process included:
This ensured that the dataset used for modelling was clean, robust, and reliable.
The bottom-up approach involved aggregating segment-level data, such as:
This method was primarily used when detailed micro-level market data were available.
The top-down approach used macro-level indicators:
This approach was used for segments where granular data were limited or inconsistent.
To ensure accuracy, a triangulated hybrid model was used. This included:
This multi-angle validation yielded the final market size.
Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.
Given inherent uncertainties, three scenarios were constructed:
Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.